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Study of the Roles of LRBA in Cancer Cell Proliferation and SHIP-1 in NK Cell
Function

Joshua John Gamsby

ABSTRACT

LRBA (LPS Responsive Beige-like Protein Kinase A anchor) gene expression is
induced by the mitogen LPS and is a member of the WBW gene family member
which is comprised of genes that are involved in cellular proliferation and
differentiation. This work provides evidence for the over-expression of LRBA in
certain cancers, and that LRBA promoter activity and endogenous LRBA mRNA
levels are negatively regulated by the tumor suppressor p53 and positively
regulated by E2F transactivators. Furthermore, we demonstrate that inhibition of
LRBA expression or function leads to decreased proliferation of cancer cells and
that LRBA plays a role in the EGFR signal transduction pathway. In addition to
the findings of LRBA’s role in carcinogenesis, this work also shows evidence of
the knockdown of the SH2-containing Inositol 5’ Phosphatase (SHIP) in both
mouse and human cells.

Furthermore, we provide evidence that SHIP-1 is

involved in the AKT signal transduction pathway in human Natural Killer cells.
vii

Chapter One
Deregulated LRBA Expression Leads to Increased Cancer Cell Survival

Introduction

The tumor suppressor p53. Transcription factors (TF) are proteins that
regulate gene expression at the level of transcription through either direct or
indirect interactions (such as when complexed to an adaptor protein) with a
genes promoter. These proteins can either activate or repress transcription of a
gene depending on the TFs specific function. In some cases, the deregulation of
a gene in cancers can be attributed to a loss of function mutation that affects
important transcription factors, such as p53 (Sherr & McCormick, 2002).
The p53 gene is a tumor-suppressor that is mutated in most types of
cancers (Vogelstein, Lane, & Levine, 2000). Tumor-suppressors are a class of
genes that are involved in regulating cellular proliferation.

Mutation or

inactivation of a tumor suppressor can lead to uncontrolled differentiation (Sherr,
2004), which is a hallmark of a cancer cell (Hanahan & Weinberg, 2000).
Furthermore, mutation of factors involved in regulating p53 activity and function
are also a cause of carcinogenesis placing p53 in a group of key tumor
suppressors whose function is critical in preventing tumorigenesis.
1

The p53

protein in particular is involved in several critical cellular processes that protect
cells from becoming carcinogenic.
The p53 protein is activated by post-translational modifications by either
intrinsic or extrinsic cellular stress events.

These modifications include

phosphorylation, acetylation, deactylation, ubiquitination, methylation, and
sumolation (Appella & Anderson, 2001) and occur through the activation of
enzymes that detect very specific cellular insults such as DNA damage, ribosome
biogenesis, hypoxia, spindle damage, temperature shock, nitric oxide, and
oncogene activation (Harris & Levine, 2005). The activation of p53 by these
stress events leads to initiation of DNA repair, apoptosis induction, and the
inhibition of cell cycle progression (Harris & Levine, 2005; Jin & Levine, 2001).
The activation of the p53 protein by these post-translational modifications affects
the p53 protein by increasing the concentration of p53 in the cell and increasing
the stability of the p53 protein. An example of this is the regulation of p53 activity
by the murine double minute 2 (MDM2) protein. MDM2 is an E3 ubiquitin ligase
which binds to p53 and ubiquitinates it, thus leading to its degradation (Bond, Hu,
& Levine, 2005). During cellular stress events such as oncogene activation, the
ARF protein initiates the degradation of MDM2 which leads to the accumulation
of p53, and thus p53 is free to perform its functions such as inducing apoptosis.
This increase in the stability and amount of cellular p53 leads to the enhanced
binding to key sequences in the promoter of genes involved in cellular
senescence, DNA repair, and apoptosis (Figure 1).

2

Figure 1. Downstream events of the tumor suppressor p53
The tumor suppressor p53 is activated during cellular stress to induce events
such as cell cycle arrest, apoptosis, DNA repair and the inhibition of metastasis
and angiogenesis.
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The E2F family of transcription factors. The E2F genes are a family of
TFs that are primarily known for their role in cell cycle progression from G1 to S
phase (DNA replication) through the transactivation of genes involved in DNA
synthesis (Dimova & Dyson, 2005; Ohtani, 1999). However, E2Fs have been
shown to be involved in other cellular processes such as cell proliferation,
differentiation, and apoptosis (Nevins, 2001). Furthermore, the E2F pathway has
been shown to be involved in both carcinogenesis and suppression of tumor
formation (Dimova & Dyson, 2005; Nevins, 2001).
In mammals, the E2F family of transcription factors is comprised of seven
genes that are known to be involved in both transcriptional activation and
repression (Dimova & Dyson, 2005).

The activation of the E2F transcription

factors requires the formation of heterodimers with DP proteins of which there
are two in mammals, DP1 and DP2 (C. L. Wu, Zukerberg, Ngwu, Harlow, & Lees,
1995). These proteins function in enhancing both the transactivation and the
DNA binding of E2F transcriptional activators (Hitchens & Robbins, 2003).
The E2F transcriptional activators are primarily comprised of three genes
E2F1, E2F2, E2F3, although some activity has been associated with E2F4
(Nevins, Leone, DeGregori, & Jakoi, 1997). These genes encode for proteins
which are expressed at various points in the cell cycle and are regulated by the
tumor suppressor RB (Figure 2). In general, the E2F transactivators function in
promoting progression of the cell cycle, while this is inhibited by E2F repressors
(Dimova & Dyson, 2005). Generation of a E2F1, E2F2, and E2F3 triple knockout mouse embryonic fibroblast cells demonstrated this conclusively as these
4

cells were unable to enter the S-phase (DNA replication) of the cell cycle (L. Wu
et al., 2001).
E2F1 in particular is one of the most studied of the E2F family of
transcription factors with over 600 articles to date available on the online
research data base PubMed (http://www.ncbi.nlm.nih.gov).

Findings have

demonstrated that the loss of E2F-1 gene in mice leads to both an increase in
tumor formation and defects in apoptosis induction (Field et al., 1996; Yamasaki
et al., 1996). Additionally, fibroblasts isolated from E2F-1 null mice have been
demonstrated to be resistant to Myc induced apoptosis (Leone et al., 2001).
Furthermore, over-expression of the E2F1 protein in tissue culture leads to an
increase in the induction of apoptosis (DeGregori, Leone, Miron, Jakoi, & Nevins,
1997) and this function is specific to the E2F1 protein and no other E2F member
(Hallstrom & Nevins, 2003).

Finally, it has been found that E2F1’s role in

apoptosis may be related to DNA damage (Wikonkal et al., 2003).

Therefore,

E2F1 is a diverse member of the E2F gene family with many ties to cancer
related processes.

5

Figure 2. The E2F family of transcription factors.
The E2F family of transactivators are represented by E2F1, E2F2, and E2F3a
and a regulated by the tumor suppressor Rb.

The tumor suppressor Rb and E2F activity. The transcriptional activators
of the E2F family are specifically regulated by the tumor-suppressor
6

retinoblastoma (RB) protein. RB is a member of a family of proteins known as
“pocket proteins” that are involved in cell cycle regulation (Cobrinik, 2005). Rb
functions to inhibit the transcription of genes required for cellular proliferation
through the recruitment of enzymes involved in chromatin remodeling (Nielsen et
al., 2001) and through protein-protein interactions with transcription factors such
as the activating E2Fs (Nevins, 2001). The latter function inhibits activating E2Fs
from binding to E2F specific sequences in the promoters of genes that are
involved in cellular proliferation, such as those involved in DNA synthesis (Figure
3).
Rb is regulated by two mechanisms, phosphorylation and degradation. In
the case of cellular proliferation, Rb is regulated primarily by phosphorylation
which prevents its interaction with E2Fs thus allowing for cell cycle progression.
The phosphorylation of Rb is performed by several cyclin dependent kinases
(Cdks) that depend on a class of proteins known as cyclins for their activity. At
the G0 (quiescent) phase of the cell cycle, mitogenic stimuli cause an induction of
several Cdks as well as cyclins and E2Fs.

This in turn, leads to the

phosphorylation of Rb and the eventual activation of E2Fs. The activated E2Fs
then initiate the transcription of more Cdks and cyclins as well as itself, leading to
an increase in the amount of inactive Rb in the cell.

In addition to being

regulated by kinase activity, Rb is also degraded by caspase activity upon
apoptotic stimuli (Chau & Wang, 2003).
Rb was the first tumor suppressor gene cloned (Classon & Harlow, 2002)
and is highly mutated in several different types of cancers (Nevins, 2001).
7

Furthermore, it has been suggested that the RB pathway itself may be
inactivated in approximately 80% of all sporadic human tumors (Chau & Wang,
2003; Sherr, 1996; Sherr & McCormick, 2002). These mutations primarily occur
in regulators of Rb function, such as p16ink4A and cyclin D1. Therefore Rb
function, as well as the factors governing its function, are critical in the prevention
of carcinogenesis.

8

Figure 3. The role of the Rb/E2F pathway in cellular growth and proliferation.
Growth stimulatory signals activate the formation of cyclin and cyclin dependent
kinase (Cdk) complexes that phosphorylate the tumor suppressor Rb. This leads
to an increase in activating and DNA synthesis ensues.
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The epidermal growth factor receptor pathway.

The epidermal growth

factor receptor (EGFR) is a Receptor Tyrosine Kinase (RTK) that is involved in
several key cellular functions such as proliferation, differentiation, apoptosis, and
migration (Fischer, Hart, Gschwind, & Ullrich, 2003). Ligand binding to the EGFR
initiates receptor dimerization and autophosphorylation which generates protein
docking sites at the phosphotyrosine residues of the C-terminus ((Figure 4,
(Jorissen et al., 2003)). This then serves as binding sites for adaptor molecules
that initiate downstream signal transduction pathways.

In addition to the

simulation of autophosphorylation by ligand binding, EGFR activity is also
stimulated by oxidative stress, UV light, γ-radiation, mechanical stress, and
hyperosmolarity (Fischer, Hart, Gschwind, & Ullrich, 2003).
EGFR is a member of a family RTKs known as the HER family that
includes Her2/neu, Her3, and Her4 (Zaczek, Brandt, & Bielawski, 2005). As
previously mentioned, EGFR can pair with itself to form a homodimer. However,
EGFR can also heterodimerize with any of the other HER family members and
the ability of these receptors to interact results in an expanded amount of signal
transduction pathways that can be stimulated by these receptors.
pathways

include

the

mitogen

activated

protein

kinase

These

(MAPK),

the

phosphotidylinositol-3 kinase (PI-3K) pathways, the JAKs and STATs pathways
(Wells, 1999).
Three of members of the HER RTK family, EGFR, HER-2/neu, and HER3,
have been implicated in carcinogenesis (Casalini, Iorio, Galmozzi, & Menard,
2004). Furthermore, over-expression of these receptors is seen in a variety of
10

cancers including in the breast, prostate, head and neck, colorectal, bladder,
ovarian, as well as non-small lung cancers (Mendelsohn, 2001). As a result, the
HER family of RTKs is a prominent target for the development of targeted cancer
therapies, such as through the development of small molecule inhibitors (Bianco,
Troiani, Tortora, & Ciardiello, 2005).

11

Figure 4. EGFR Activation
The epidermal growth factor receptor is activated by ligand binding which
induces heterodimerization followed by autophosphorylation. This creates a
docking site for a variety of proteins that are involved in several signal
transduction processes.
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Properties of the LRBA gene and protein. The LRBA (LPS Responsive
Beige-like Protein Kinase A anchor) gene was discovered through a gene
trapping method which identified genes that were simulated by the mitogen LPS
(lipopolysaccharide) (Kerr, Heller, & Herzenberg, 1996).
expression

is

upregulated

in

cells

responsive

to

Thus, LRBA gene
mitogen

stimulation.

Furthermore, LPS simulation can induce LRBA to associate with several
structures in the vesicular system such as endoplasmic reticulum, Golgi, plasma
membrane, and endocytosis vesicles (J. W. Wang, Howson, Haller, & Kerr,
2001).

Additionally, the LRBA gene also encodes for 3 potential isoforms.

However, the function of the LRBA gene and the protein it encode(s) for has yet
to be determined.

LRBA and the WBW gene family. LRBA is a member of a unique family of
genes known as the WBW family. The WBW domain is a multidomain structure
located at the C-termini of each protein (J. W. Wang, Howson, Haller, & Kerr,
2001). This unique super-domain contains three subdomains: WDL (WD-like),
BEACH, and WD40. The WDL (WD-like) domain contains a potential Pleckstrin
Homology (PH) domain as determined through X-ray crystallography of
neurobeachin, a WBW gene family member (Jogl et al., 2002). These domains
are known to be involved in the binding of the phospholipids and proteins
(Blomberg, Baraldi, Nilges, & Saraste, 1999).

Biochemical and structural

evidence suggests that the PH domain of LRBA is unable to bind to phospholipid
structures when complexed to the BEACH domain (Gebauer et al., 2004).
13

However, the WDL domain alone was not considered, nor was the possibility that
this association may be intrinsically regulated; therefore more investigation is
needed to determine the relevance of this domain.
The BEACH (Beige and CHS) domain is highly conserved across all of the
WBW family members and is known to be mutated in individuals with Chediak
Higashi Syndrome (CHS) (Nagle et al., 1996). This is an autosomal recessive
disorder characterized by impaired vesicular trafficking (Spritz, 1998). WD40
domains are a stretch of Tryptophan and Aspartate residues that are known to be
involved in protein-protein interactions (Li & Roberts, 2001). The LRBA protein
also contains a potential Protein Kinase A (PKA) anchor domain (J. W. Wang,
Howson, Haller, & Kerr, 2001). The presence of these domains in the LRBA
protein indicates that this protein may possibly be involved in interactions with
phospholipids, proteins, and PKA.
Although the function of the LRBA protein has yet to be determined, WBW
gene family members provide clues as to what role LRBA may be playing in the
cell. Neurobeachin is a WBW family member which is primarily expressed in
neural tissue (X. Wang et al., 2000) whose function is critical for neuromuscular
synapse transmission (Su et al., 2004). Lvsa (large volume sphere A) in the
organism Dictyostelium has been shown to be involved in cytokinesis (Kwak et
al., 1999). Another orthologue of LRBA, rugose/AKAP550 has been determined
to interact with several signal transduction pathways such as EGFR, Notch, and
Ras through genetic studies (Shamloula et al., 2002). FAN (factor associated
with neural sphingomyelinase) is associated with TNF (tumor necrosis factor)
14

induced apoptosis (Segui et al., 2001). Furthermore, it has been shown that
rugose/AKAP550 mutations induce apoptosis in the cone cells of the Drosophila
eye (Wech & Nagel, 2005).
One interesting theme that stands out with several of these genes and
their protein products is that several of the processes that they are involved in
are either deregulated or subverted by a cancer cell. This combined with the
evidence depicting LRBA expression is stimulated by a mitogen (LPS) prompted
the hypothesis that LRBA expression might be deregulated in a cancer cell.
The characterization of novel genes involved in carcinogenic processes is
important to the overall understanding of this disease. This includes not only
determining the function of the products of these new genes, but also how their
expression is regulated.

Through this, new treatments and therapies are

possible. This chapter characterizes the role LRBA plays in carcinogenesis.

Results

LRBA expression is upregulated in a variety of cancers. Microarray is a
technique used to screen the expression pattern of mRNA levels across several
thousand genes, and in some cases, an entire genome simultaneously (Schulze
& Downward, 2001). Total RNA or mRNA is isolated from the tissue of interest
and converted to cDNA by reverse transcriptase PCR.

This cDNA is then

labeled with a fluorescent dye and these labeled cDNAs are then hybridized to a
“gene chip” which contains the individual cDNAs of several thousand genes of an
15

organism. Fluorescence is measured and quantified and statistical programs are
then used to crunch the data from the amount of signal measured.
This technique was employed to screen the expression of LRBA mRNA
levels in various cancers in both primary tissues and various cancer cells lines.
Results show that LRBA is upregulated in renal, colorectal, pancreas, lung and
CNS carcinomas as compared to normal tissue controls (Figure 5a and b).
Screening of a lung cancer microarray database also showed that LRBA mRNA
expression is also upregulated in adenocarcinoma, carcinoid, and small-cell lung
cancers (Figure 5c, (Bhattacharjee et al., 2001)). Additional microarray analysis
showed that LRBA mRNA levels were significantly higher in 27 human breast
tissue samples as compared to 6 normal tissue controls. Furthermore, mRNA
levels were also significantly higher in estrogen receptor (ER) positive breast
cancer cells as compared to ER negative cells (Table 1). Breast cancers that are
ER positive require hormone therapy to block proliferation.

Therefore, it is

possible that LRBA targeted therapy could possibly increase the efficacy of these
treatments.
Although microarray is a powerful tool to measure mRNA expression,
further validation is needed to verify results garnered from this technique. To this
end, we employed quantitative real time rtPCR (reverse transcriptase
Polymerase Chain Reaction) to test the mRNA of LRBA in various cancers and
normal tissues.

Real time rtPCR is an improved reverse transcriptase PCR

method that allows one to quantify the amount of product generated during the

16

PCR reaction, where as with a traditional rtPCR assay, results are solely
qualitative (Bustin, 2002).
There are several real time PCR methods that can be used to quantify
mRNA levels. In this case, the SYBR Green method was employed due to the
ease of primer design and low cost as compared to others such as the Taqman
method which requires expensive probes in addition to reagent and primer costs.
SYBR Green is a DNA intercalating fluorescent dye which allows for the
detection of double stranded DNA during the PCR reaction (Arya et al., 2005).
As with microarray, total RNA is isolated from the tissues of interest and
converted to cDNA by reverse transcription.

However, the cDNA is then

combined with primers specific for the gene of interest, SYBR Green, and rtPCR
is performed using a device that not only is capable of cycling the temperature
required for PCR, but of detecting fluorescence.

Therefore, the amount of

product produced through each cycle of amplification can be measured by the
detector and therefore quantified.
LRBA mRNA levels in both prostate and breast cancer cells were assayed
by this method. Primary tissues were used for RNA isolation from patients with
prostate and breast cancer. Normal tissue biopsied outside the area of tumor
growth was used as a source for control mRNA levels. Real time PCR analysis
showed a significant increase in LRBA mRNA levels in both prostate and breast
cancers as compared to the normal tissue controls (Figure 6a and b).
Furthermore, RNA was isolated from the breast cancer cell line MCF7 and the
transformed breast epithelial cell line MCF10A. Real time rtPCR analysis also
17

showed significantly higher levels of LRBA mRNA in MCF7 cells as compared to
the MCF10A’s (Figure 6b).

18
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Figure 5. Microarray analysis shows elevated LRBA expression levels in certain
cancers.
(a) LRBA mRNA expression is elevated in tumor tissues isolated from renal
(Kidney, P = 0.0013) , pancreas (Panc, P = 0.0414), colorectal (Colore, P =
0.0001, ), and lung (P < 0.0001) as compared to normal tissue isolates. Sample
sizes ranged from each group from 10 to 36. (b) LRBA mRNA expression is
elevated medulloblastoma (Med, P = P = 0.0001), rhabdomyosarcoma (Rha, P =
0.0058), but not in gliobastoma (gli) tumors as compared to normal tissue
isolates.

(c)

LRBA mRNA expression is elevated in carcinoid (Carc, P <

0.0001), adenocarcinoma (Adeno, P = 0.0488), small-cell (Small, P = 0.0073),
but not in squamous (Squa, P = 0.5839) lung tumors.

20

Table 1. LRBA expression is higher in ER+ tumors then in ER- tumors.

21

Figure 6.

Real time rtPCR results shows that LRBA mRNA expression is

elevated in primary cancers and cancer cell lines.
(a) LRBA mRNA expression is elevated in prostate cancers from patient tissues
as compared to normal tissue; patient 1, P = 0.0164, patient 2, P = 0.0379. (b)
LRBA mRNA levels are elevated in breast cancer cells in both patient samples
(patient 3, P = 0.0164) and in the MCF7 cells as compared to MCF10A’s (P <
0.0001). LRBA mRNA levels were normalized to β- Actin levels.
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LRBA promoter activity is negatively regulated by p53 and positively
regulated by E2F1.

As LRBA mRNA expression is deregulated in various

cancers, it was apparent that this might be due to the loss of transcriptional
control of the LRBA gene.

To this end, the putative LRBA promoter was

identified through SMART (switching mechanism at 5’ end of transcript) 5’ RACE
(rapid amplification of cDNA ends). This method allows for the identification of
the complete 5’ sequence of a cDNA of interest, thereby allowing for the
identification of putative transcriptional initiation sites after sequencing.
Furthermore, SMART 5’ RACE is an improved form of the RACE technique that
allows for the amplification of longer cDNAs with a complete 5’ sequence, thus
making this technique more suitable for our purposes in identifying the LRBA
transcriptional initiation site (Zhu, Machleder, Chenchik, Li, & Siebert, 2001).
After the 5’ cDNA of LRBA was sequenced, the LRBA putative LRBA promoter
was

identified

and

a

TF

search

was

performed

using

the

MOTIF

(http://motif.genome.jp/) algorithm which identifies potential TF binding sites
based on known TF binding sequences.

Through this, several possible TF

binding sites were identified in the LRBA promoter. However, three potential
TF’s stood out as being the most relevant to carcinogenesis. These included
possible ER, p53, and E2F1 binding sites (Figure 7).
To explore whether or not LRBA promoter activity is regulated by p53 and
E2F1, reporter assays were performed.

One method of detecting promoter

activity is through luciferase assays. This assay is based on the properties of
luciferase, an enzyme that cleaves its substrate luciferin which generates
23

photons that can be detected by a luminometer. DNA plasmid constructs were
made containing the LRBA promoter sequence driving the production of
luciferase. In the case of p53, the LRBA luciferase reporter plasmid was cotransfected with either a p53 wild-type or p53 DNA binding mutant encoding
construct into the lung adenocarcinoma cell line H1299. The H1299 cell line is
deficient for p53 expression, thus this cell line is an excellent model for the
reporter assay as no endogenous functional p53 is present. Therefore, the only
effect observed should be from the p53 encoded by the wild-type p53 construct.
Results from this assay show that wild-type p53 significantly represses LRBA
promoter activity as compared to the DNA binding mutant (Figure 8).
To further validate these results, a second reporter assay was performed.
In this case, a green fluorescent protein (GFP) encoding LRBA promoter
construct was used in place of the luciferase construct to determine LRBA
promoter activity. A LRBA promoter construct driving the synthesis of GFP was
co-transfected with either the wild-type p53 or p53 DNA binding mutant
producing construct. GFP levels were then detected by flow cytometry. This
technique utilizes the excitation of fluorochromes present either on the surface or
internally, which then emit at a specific frequency that can be detected and
quantified as single cells pass through a detector in a fluid stream. In this case,
this method was used to detect GFP expression. Results from this experiment
agreed with the previous luciferase assays in that LRBA promoter activity was
significantly repressed in the presence of wild-type p53 as compared to the p53
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DNA binding mutant (Figure 9). Taken together, these data strongly suggest that
LRBA promoter activity is negatively regulated by the tumor suppressor p53.
As with p53, luciferase assays were performed to determine whether
E2F1 influences LRBA promoter activity. In this case, the glioblastoma cell line
T98G was chosen as it has functional RB which can sequester endogenous
E2Fs making it as suitable model for the reporter assay. Co-transfection of either
an E2F1 wild-type or DNA binding mutant producing construct with the LRBA
promoter luciferase construct showed a significant increase in LRBA promoter
activity (Figure 10). Furthermore, additional luciferase assays with the two other
activating E2F transcription factors, E2F2 and E2F3a, showed a significant
increase in LRBA promoter activity as compared to the DNA binding mutant
(Figure 11). This indicates that LRBA promoter activity is positively regulated by
activating E2Fs.
Although reporter assays are a good way to measure the regulation of a
gene’s promoter, we felt further work was needed to validate whether or not
LRBA is truly regulated by both p53 and E2F1. In the case of p53, the wild type
encoding construct or an irrelevant control plasmid (pBluescript) was transfected
into the H1299 cells and quantitative real time rtPCR was performed to detect
endogenous LRBA mRNA levels. Results show that LRBA mRNA levels are
significantly decreased in the presence of wild-type p53 as compared the
pBluescript control plasmid (Figure 12, left). A similar approach was used for
E2F1 in that wild-type E2F1 encoding or pBluescript plasmid was transfected into
T98G cells and quantitative real time rtPCR was used to detect endogenous
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LRBA mRNA levels. Consistent with the luciferase data, LRBA mRNA levels
were significantly increased in the presence of wild-type E2F1 as compared to
the pBluescript control plasmid (Figure 12, right). Taken together, these results
clearly show that both LRBA promoter activity and transcription is negatively
regulated by p53 and positively regulated by activating E2Fs.
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Figure 7. Characterization of the LRBA promoter.
The LRBA promoter sequence with the DNA consensus binding sites for various
transcription factors underlined.
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Figure 8. The LRBA promoter is negatively regulated by p53.
LRBA promoter activity is down-regulated in the presence of wild-typ3 p53, but
not in the presence of a DNA-binding mutant. Luciferase assay were performed
in quadruplicate. P = 0.0067 (pLA-luc vs pLA-luc + p53wt).
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Figure 9. The LRBA promoter activity is down-regulated by p53.
A LRBA promoter construct driving GFP expression was co-transfected with
either a p53 wild-type encoding construct or a p53 DNA-binding mutant in H1299
cells. Two separate experiments are presented.
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Figure 10. The LRBA promoter is upregulated by E2F1
LRBA promoter activity is upregulated in the presence of wild-type E2F1, but not
by a DNA-binding mutant. Luciferase assay were performed in quadruplicate. P
< 0.0001 (pLA-Luc vs pLA-Luc + E2F1wt).
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Figure 11. LRBA promoter activity is up-regulated by E2F family transactivators.
The LRBA promoter construct driving luciferase production was co-transfected
with wild-type constructs encoding either E2F1, E2F2, or E2F3a in T98G cells.
Luciferase assay were performed in quadruplicate.
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Figure 12. Endogenous LRBA mRNA expression is down-regulated by p53 and
up-regulated by E2F1.
Real time rtPCR results of H1299 cells co-transfected with wild-type p53
construct (left) show repression of LRBA promoter activity (P = 0.0013) while
T98G cells co-transfected with an E2F1 (right) show activation of LRBA promoter
activity (P = 0.0003) as compared to a transfection control (p-Bluescript). Results
were normalized to β-Actin levels and were performed in triplicate.
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Repression of LRBA mRNA expression by RNAi results in the death of
human cancer cells. The finding that LRBA expression is increased in certain
cancers and that LRBA promoter activity is regulated by both p53 and activating
E2Fs prompted us to pursue whether the repression of LRBA expression in
cancer cells could inhibit proliferation and/or survival.

To this end, RNAi

techniques were utilized to inhibit LRBA mRNA expression.
RNA interference is a sequence specific technique utilized to inhibit mRNA
expression of a target gene.

This involves the delivery of either small RNA

duplexes known as small inhibitory RNA’s (siRNA’s) or plasmid DNA encoding
for small hairpin RNA’s (shRNA’s) (Hannon & Rossi, 2004). These small RNA’s
are then processed by the ribonuclease DICER and are incorporated into the
RNA Induced Silencing Complex (RISC) which then degrades the target mRNA
(Meister & Tuschl, 2004).

This process was first discovered in plants and

characterized in the organism C. elegans (Fire et al., 1998) and later utilized as a
technique for gene inhibition in mammalian cells (Elbashir et al., 2001).
siRNA’s specific for LRBA were designed and transfected into HeLa cells.
Microscopy of transfected cells show that cells transfected with LRBA specific
siRNA’s have a dramatic impact on the morphology of these cells as compared
to non-specific “scrambled” control siRNA’s (Figure 13a). These control siRNA’s
have no known specificity to any human gene, but are presumed to still obtain
the ability to be loaded into the RISC complex and otherwise function as an
siRNA without inhibiting gene expression. Trypan blue cell viability counts show
a significant reduction in HeLa viable cells transfected with LRBA specific
33

siRNA’s as compared to control transfected cells, and cells treated with growth
media alone (Figure 13b).

To determine whether the effect on viable cell

numbers is specific to cancer cells, and not to any human cell type, LRBA
specific siRNA’s were tested for their ability to inhibit cell viability in both a breast
cancer cell line (MCF7) and a non-tumorigenic breast epithelial cell line
(MCF10A). Results show a significant reduction in the numbers of viable MCF7
cells when treated with LRBA specific siRNA’s as compared to both media and
siRNA control treated cells. However, no such reduction of cell viability was
observed in the MCF10A treated cells (Figure 14).
In addition to developing LRBA specific siRNA’s, shRNA’s were also
constructed. These shRNA’s were then tested for their ability to inhibit cancer
cell viability and proliferation.

To determine whether the inhibition of LRBA

mRNA expression has an effect on cancer cell proliferation, a colony forming
assay was utilized. Results show that LRBA specific shRNA transfected HeLa
cells were much less able to form colonies as compared to HeLa cells
transfected with a non-specific control shRNA plasmid (Figure 15). Furthermore,
validation of the siRNA approach demonstrating LRBA specific inhibition of
cancer cell proliferation was also evident with the shRNA approach as seen in
MCF7 cells, and rtPCR analysis confirmed the inhibition of LRBA transcription
(Figure 16).
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Figure 13. LRBA specific siRNA’s inhibit cancer cell growth.
(a) Morphology of HeLa cells transfected with either a non-specific control siRNA
or a LRBA-specific siRNA. (b) Growth of HeLa cells is inhibited by a LRBAspecific siRNA as compared to a non-specific control siRNA (P = 0.0006), or to
cell treated with transfection media alone.
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Figure 14. LRBA specific siRNA’s inhibit cancer cell proliferation.
LRBA-specific siRNA’s inhibit the growth of MCF7 cells (top), but not that of
MCF10A’s (bottom). Two LRBA-specific siRNA’s (targeting two different regions
of the LRBA mRNA sequence) were transfected and compared to a non-specific
control siRNA. * P-values are 0.0009 (siRNA1)and 0.0005 (siRNA2).
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Figure 15. LRBA-specific shRNA vector inhibits cancer cell proliferation.
Colony-forming assay shows that LRBA-specific shRNA’s inhibits the colony
forming ability of HeLa cells (left). Colonies were quantified (right) which shows
that this decrease is statistically significant (P = 0.0186).
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Figure 16. LRBA specific shRNA’s inhibits cancer cell proliferation and LRBA
transcription.
LRBA-specific shRNA’s inhibit the proliferation of both HEK293 and MCF7 cells
as compared to cells transfected with a non-specific control shRNA plasmid (top).
rtPCR results show that the LRBA-specific shRNA plasmid inhibits the
expression of LRBA mRNA in HeLa cells as compared to a non-specific control
and β-Actin levels show equal loading (bottom).
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Inhibition of LRBA activity by a Dominant-Negative mutant also inhibits the
proliferation of human cancer cells.

Although our data depicting inhibition of

LRBA mRNA levels can lead to a dramatic decrease in proliferation and
tumorgenecity of cancer cells, a second approach targeting the presumed
function of LRBA was utilized to demonstrate this effect through the use of a
dominant negative mutant. Adam-Klages et al. have shown that the BEACH and
WD40 domain of the FAN can act as a dominant-negative mutant that inhibits its
function (Adam-Klages et al., 1996). Therefore, an adenoviral plasmid construct
encoding the LRBA BEACH and WD40 domain was constructed and tested for
its ability to act as a dominant-negative mutant.

This construct contains a

promoter driving the expression of GFP and a tetracycline repressor element
that, when in the presence of the antibiotic Doxycycline, inhibits gene
transcription. Transfection of MCF7 cells with this construct shows a significant
reduction in the ability to proliferate as determined by a 3H thymidine uptake
assay (Figure 17). In this assay, radiolabeled thymidine (3H thymidine) is added
to the cellular media and is subsequently incorporated into cellular DNA during
each round of cellular division.

Then, radioactivity is then measured with a

scintillation counter. Western blot analysis showed that the construct expresses
the dominant-negative mutant and that this expression is repressed in the
presence of doxycycline. Furthermore, microscopy analysis of GFP levels also
confirmed this finding (Figure 18).
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Figure 17. Proliferation of MCF7 is inhibited by adenovirus encoding for a LRBA
dominant negative mutant (AdBWGFP).
Increasing amounts of AdBWGFP virus was added to MCF-7 cells containing
media with or with out doxycycline. A cell proliferation assay shows that the
AdBWGFP inhibits the growth of MCF7 cells.
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Figure 18. AdBWGFP expression is controlled by doxycyline
(b) AdBWGFP expression is tightly controlled by Doxycycline as demonstrated
by western blot analysis.

β-Actin levels show equal loading of protein.

(c)

Fluorescence microscopy further demonstrates that BWGFP expression is
controlled by doxycycline.
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LRBA knockdown sensitizes cancer cells to apoptosis. The finding that
LRBA expression is important for cancer cell growth and viability led us to next
question whether the inhibition of LRBA expression could sensitize cancer cells
to apoptosis. To test this, LRBA specific siRNA’s were again used to inhibit
LRBA mRNA expression in the presence of known apoptosis inducing agents
such as UV light and chemotherapeutics. HeLa cells were transfected with either
control or LRBA-specific siRNA’s and then treated with UV or Staurosporine, a
known apoptosis inducing chemical.

Cell viability counts show a significant

reduction in cell numbers of LRBA-specific siRNA treated HeLa cells in which
apoptosis was induced as compared to untreated siRNA transfected cells.
Furthermore, cell numbers were significantly decreased in apoptosis induced
cells when LRBA expression was inhibited (LRBA siRNA treated cells) as
compared to control treated cells (control siRNA and H2O treated) (Figure 19).
To further test whether the inhibition of LRBA expression can enhance
apoptosis in cancer cells, western blot analysis was performed on siRNA treated
HeLa cells (see above) to determine the effect on known players in the apoptosis
signal transduction pathway. Caspase 3 is an executioner of apoptosis and a
member of a family of cysteine proteases which are activated during apoptosis
(Porter & Janicke, 1999). Caspase is a zymogen which is activated by cleavage
during either extrinsic or intrinsic apoptosis inducing events. Poly (ADP-Ribose)
Polymerase or PARP is an enzyme involved in DNA repair and is a substrate for
caspase 3 (Decker & Muller, 2002). Results show a significant increase in both
PARP and Caspase 3 levels after apoptosis induction, and this is further
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increased when LRBA mRNA expression is inhibited (Figure 20). Cisplatin is a
conventional chemotherapeutic that induces the apoptosis. Inhibition of LRBA in
addition to treatment with cisplatin showed a significant decrease in cellular
proliferation as compared to cisplatin treatment alone suggesting that LRBA may
be a target for future development of anti-cancer drugs (Figure 21).
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Figure 19.

LRBA protects HeLa cells from apoptosis induced by UV or

staurosporine.
LRBA-specific siRNA transfected HeLa cells show an enhanced sensitivity to
either UV or staurosporine treatment as compared to control treated HeLa cells.
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Figure 20. Staurosporine and UV treated LRBA-specific siRNA treated HeLa
cells show increased PARP and Caspase 3 cleavage.
HeLa cells transfected with either a LRBA-specific siRNA or a control siRNA and
apoptosis was induced with UV or staurosporine. Western blot analysis shows a
significant increase in cleaved PARP and Caspase 3 levels in the LRBA-specific
siRNA treated cells as compared to controls. Β-Actin levels show equal protein
loading.
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Figure 21. Inhibition of LRBA expression leads to an increased sensitivity to the
chemotherapeutic drug cisplatin.
HEK293 cells transfected with the LRBA-specific shRNA show an increased
sensitivity to cisplatin as compared to cells transfected with a non-specific control
(P = 0.0029).

46

LRBA is involved in EGFR signaling. As previously mentioned, the LRBA
orthologue, rugose/AKAP550, has been shown to interact with the EGFR
pathway through genetic studies (Shamloula et al., 2002). Therefore, we tested
whether LRBA is also involved in EGFR signaling.

Additionally, we tested

whether a downstream player in the EGFR signal transduction pathway, MAP
Kinase (MAPK) is also influenced by LRBA. To this end, the LRBA dominant
negative mutant was again used to inhibit LRBA function.

HeLa cells were

transfected with the dominant negative LRBA mutant with our without the
presence of EGF or doxycycline. Western blot analysis showed reduced levels
of activated EFGR (phosphorylated) when LRBA function was inhibited (Figure
22). Furthermore, this effect was seen with increasing concentrations of EGF
and at two different time points after EGF stimulation.

Activated MAPK

(phosphorylated) levels were also decreased in the absence of LRBA function.
However, this effect was not as immediate as with EGFR and more EGF was
required to elicit a response. This is expected as activated EGFR is upstream of
MAPK, and therefore a lag response in MAPK activation was anticipated.
Furthermore, the requirement of more EGF may be due to the reduced levels of
activated EGFR at the smaller dosage. Finally, EGFR and MAPK levels remain
unchanged indicating that LRBA and β-Actin levels show equal loading of
protein. These results suggest that LRBA may play a role in EGFR signaling.
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Figure 22. LRBA is involved in the regulation of EGFR signaling.
AdBWGFP treated HeLa cells were treated with increasing amounts of EGF in
the presence or absence of doxycycline.

Western blot analysis shows a

decrease in activated EGFR levels in the absence of doxycycline as compared to
cells treated with doxycycline.
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Discussion

The results presented show that LRBA expression is upregulated in
various cancers as observed through microarray analysis and levels of LRBA
mRNA expression vary depending on the tumor type. Furthermore, LRBA mRNA
levels are much higher in ER positive tumors as compared to ER negative
tumors. This suggests that LRBA’s function in certain cancers may be important
and warranted further investigation.

Additionally, LRBA may play a more

important role in ER positive tumors which are dependent on estrogen for
proliferation, thus traditional hormone therapies combined with LRBA targeted
therapies could possibly increase the efficacy of these treatments. Furthermore,
this suggests a possible link between LRBA function and ER stimulated
proliferation providing the basis for future investigation.
Characterization of the LRBA promoter sequence yielded several
interesting putative transcriptional regulatory sites including a CpG island, a
possible ER binding site, and several transcription factor binding sites such as
E2F and p53. The presence of the potential ER binding site is of interest due to
the increased amount of LRBA expression in ER+ tumors. This provides an
explanation as to why LRBA levels are higher in these tumors and should be
explored further.
The p53 sites provided interest as this tumor suppressor’s function is
critical in cell survival and is highly mutated in cancers (see introduction).
Investigation showed that p53 negatively regulates both LRBA promoter activity
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and the expression of endogenous LRBA mRNA levels. This provides further
credence to the idea that LRBA function may be critical for cancer cell survival
and a reason as to why LRBA expression is deregulated in certain cancers. As
previously mentioned, p53 activity is induced in cellular crisis events, such as
DNA damage, and this activity leads to either cellular senescence or apoptosis.
Therefore, it’s possible that when p53 is non-functional in a cancer cell, due to
either mutation of p53 or a regulator of p53 activation, regulation of LRBA
expression is lifted and is thus over-expressed. Therefore, LRBA would be free
to perform its function of aiding cancer cell proliferation and survival.

This

provides an intriguing explanation as to why LRBA is over-expressed in such a
wide variety of cancers. Additionally, this evidence also suggests that LRBA may
possibly play a role in suppressing apoptosis, and therefore, p53 must inhibit
LRBA expression in order for apoptosis to ensue. Furthermore, these findings
provide the basis for future investigation as to the role LRBA plays in the cell
during crisis events.
In addition to the finding that p53 negatively regulates LRBA, our results
show that both LRBA promoter activity and endogenous mRNA levels are
positively regulated by the activating E2F transcription factors. As the activating
E2Fs are regulated by the tumor suppressor RB, this provides another interesting
explanation as to why LRBA expression is upregulated in certain cancers. As
with p53, Rb, or its regulators, are highly mutated in wide range of cancers (see
introduction).

Since LRBA is positively regulated by activating E2Fs, one

explanation for the over-expression of LRBA mRNA levels in cancer cells could
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be due to loss of Rb function causing increased E2F activity and thus increased
LRBA expression.

Furthermore, it’s possible that this increase in LRBA

expression through E2F induction could facilitate cancer cell proliferation or
survival.
Interestingly, the E2F and p53 pathways also intersect through the tumor
suppressor ARF during stress events to induce apoptosis (Bates et al., 1998).
During cellular stress, E2F1 induces the expression of ARF which initiates the
degradation of MDM2.

This prevents the subsequent ubiquitination and

degradation of p53, thus stabilizing its expression (La Thangue, 2003).
Therefore, it’s possible that when p53 expression is stabilized by the E2F1
induction of ARF, LRBA expression would subsequently be decreased.
Consequently, whatever role LRBA may play in preventing apoptosis in potential
cancer cells would be alleviated. Although E2F1 upregulates LRBA expression,
and in this model E2F1 activity is responsible for the stabilization of p53
expression, it is possible that p53 repression of LRBA expression supersedes
that of E2F1 activation. Thus, E2F1 could play a duel role in regulating LRBA
expression by directly upregulating LRBA expression during cellular proliferation
and negatively regulating LRBA expression indirectly through ARF-p53 pathway
during cellular stress.

This connection provides interesting new venues to

explore in the transcriptional regulation of LRBA.
The findings that LRBA is regulated by both p53 and E2F1 combined with
discovery that LRBA expression is upregulated in certain cancers prompted us to
investigate whether the inhibition of both LRBA expression and function could
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impact cancer cell proliferation.

Our results show that inhibiting LRBA

expression leads to a decrease in cancer cell viability and proliferation.
Furthermore, we observed that cancer cells demonstrated an increased
sensitivity to apoptosis inducing agents and to the chemotherapeutic cisplatin.
This clearly suggests that LRBA expression and function may be vital to the
survival of a cancer cell and that targeting LRBA may be an effective way to aid
current cancer therapies.
To date, the function of the LRBA protein is unknown. Genetic results
from the LRBA orthologue rugose/AKAP550 show that this gene may be involved
in EGFR signaling. Therefore, we then assayed for LRBA’s ability to interact with
the EGFR pathway and results indicated this to be so. Since LRBA appears to
be important for the survival of cancer cells, this seems like a logical signal
transduction pathway for LRBA’s involvement.

Furthermore, through the

combined findings of LRBA transcriptional regulation and EGFR signaling, an
interesting model arises (Figure 23). However, more work needs to be done to
determine exactly what role LRBA plays in this pathway, and how this role relates
to LRBA’s involvement in cancer cell survival.
In summary, the results presented show that LRBA is upregulated in
various cancers, and that LRBA transcription is negatively regulated by p53 and
positively regulated by activating E2Fs.

Furthermore, inhibition of LRBA

expression and function leads to a decrease in cancer cell proliferation and
sensitizes cancer cells to apoptosis inducing agents. Finally, our results show
that LRBA plays a role in EGFR signaling.
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Figure 23. Possible role of LRBA interaction with the EGFR pathway.
LRBA enhances EGFR signaling and leads to the activation of E2F1, which
feeds back to activate the expression of LRBA. The positive feedback of the
stimulation of LRBA expression by E2F1 leads to enhanced EGFR signaling, and
thus cellular proliferation.

p53 acts to antagonize this by repressing LRBA

expression during cellular stress events.
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Materials and Methods

Reagents.

Restriction enzymes were purchased from New England Biolabs

(Beverly, MA); PCR primers were purchased from Integrated DNA Technologies
(Coralville, IA); [3H]Thymidine from NEN (Boston, MA); fetal bovine serum from
Invitrogen (Gaithersburg, MD) anti-GFP antibody from Santa Cruz Biotechnology
(Santa Cruz, CA); staurosporine and cisplatin Sigma (St. Louis, MO);
SuperSignal West Femto Kit from Pierce Biotechnology (Rockford, IL), G418 and
DNA rapid ligation kit from Roche Diagnostics (Manheim, Germany); EGFR,
phospho-EGFR, MAPK, phosphor-MAPK, (Thr202/Thr204), PARP, and caspase
3 antibodies from Cell Signaling Technologies (Beverly, MA).

Cell culture.

Cell lines were purchased from ATCC (Manassas, VA) and

maintained by following culturing protocol’s outlined by ATCC for each cell line.

Microarray.

In all experiments, 5ug of total RNA was used to generate the

mRNA for microarray analysis. cDNA was generated from the mRNA by rtPCR
and labeled with biotin as described by Van Gelder et al. Hybridization of the
biotin labeled DNA, staining, and scanning of the chips was performed by
following the manufacturer’s instructions (Affimetrix, Santa Clara, CA) and as
previously described (Warrington et al., 2000). The Affymetrix oligonucleotide
array chips used were U95A and HU6800. Output files from scanned chips were
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inspected for hybridizations artifacts and analyzed by using the Affymetrix
Microarray Software version 4.0. Some microarray data was provided by R Jove
and G Bepler at the H. Lee Moffitt Cancer Center (Bloom et al., 2004).

rtPCR and Real Time rtPCR. RNA was isolated from 5 x 105 cells and purified
with the RNAqueos 4-PCR Kit (Ambion, Austin, TX) following the manufacturer’s
protocol. cDNA was then generated by using oligo-dT primers and Supercript II
reverse transcriptase (Invitrogen, Carlsbad, CA) following the manufacturer’s
protocol. The synthesized cDNA mixture was then diluted at 1:10 and used (2–4
ml)

for

either

PCR

with

the

primers

TCACCCCAAAAGGATTAGATGGACC-3,’

for

LRBA:

and

GAAAGAAAGGCTCTGCGAACCTCC-3’;

for

TGACGGGGTCACCCACACTGTGCC-3’

5’5’-

β-actin:
and

5’5’-

TAGAAGCATTTGCGGTGGACGATG-3’, or by real-time PCR with the primers –
for

LRBA:

5’-CCAACTTCAGAGATTTGTCCAAGC-3’

ATGCTGCTCTTTTTGGGTTCAG-3’;
ATTGCCGACAGGATGCAGAA-3’

for

and

β-actin:

and

5’5’-

5’-GCTGATCCACATCTGCTGGAA-3’.

ABI Perkin-ElmerPr ism 7700 Sequence Detection System (Applied Biosystems,
Inc., FosterCit y, CA, USA) and SYBR Green Quantitect MasterMix (Qiagen,
Valencia, CA, USA) were used for real time PCR following the manufacturer’s
protocol.
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RACE and determination of the transcription start sites.

Switching

mechanism at 5’ end of RNA transcript (SMART) rapid amplification of cDNA
ends (RACE) amplification kit (Clontech, Palo Alto, CA, USA) was used to map
the 5’ end of LRBA gene transcripts.

The 5’ cDNA of LRBA gene was

synthesized from 2.5 µg of normal prostate or prostate tumor total RNA by
reverse transcription using the PowerScript Reverse Transcriptase (Clontech)
and LRBA-specific primer 5’-CACACAGAGCATTGTAGCAAGCTCCTC-3’. The
first PCR reaction was carried out using the LRBA specific primer 5’GGGCACTGGGGAGAATTTCGAAGTAGG-3’

and

UPM

primer

provided,

following the manufacturer’s recommendation. Primers for the secondary PCR
amplification are 5’-TGCAGACTTGAAGATTCCG-3’ and the NUP primer
provided. The Advantage polymerase mix (Clontech) was used for these PCR
amplifications. The PCR products were cloned and sequenced.

Cloning and sequencing of the LRBA promoter. Based on the genomic
sequence in GenBank (AC011122) and our sequences from 5’ RACE, we
designed PCR primers to amplify a 2 kb putative promoter fragment from human
genomic DNA extracted from MCF-10A cells by DNeasy tissue kit (Qiagen). The
primers are: 5’CGCCTCGAGCGGCTTCT
GTCCACTTCTCAAGGC3’

and

5’-

CCCAAGCTTATCTCTCTCCCCGAGGCTGACAAC-3’.

The amplification was

carried out by using the Advantage-GC Genomic PCR Kit (Clontech) and 5 µl
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GC-Met for 50 µl PCR reaction, following the manufacturer’s recommendation.
This 2 kb PCR product was cloned into the pGL2 vector or (Promega, Madison,
WI, USA) to obtain the pLA-luc luciferase reporter vector or the pEGFPN1
(Clonetech) vector to obtain the LRBA-GFP vector. Sequencing of the LRBA
promoter was performed by the following primers: 5’-TGCGAGTGGTGAGGATG3’,

5’-GACGGAAGGGTCTCTCCT-3’,

5’-TGCGAGTGGTGAGGATG-3’,

5’-

CGAGCTAATCTTCACATTG-3’ and 5’-TTCCTCACCCAGATACTCCG-3’.

Luciferase assays for LRBA promoter analysis. Cells were seeded 24 h
prior to transfection in a 24-well plate at a density of 1 x 105 cells per well. The
pLA-luc vector was co-transfected with p53 or E2F gene expression vectors into
H1299 orT98G cells using Lipofectamine 2000 (Invitrogen) following the
manufacturer’s protocol. For p53 assays, the vectors pCMV-p53 or pCMV-p53
mt135 (Clontech) were used.

ForE2F assays, pcDNA E2F1wt, pE2F2wt,

pE2F3a and pcDNAE2F1eco132 were used.

In all experimental systems, a

Renillan luciferase control vector, pRL-TK, pRLCMV,
or pRL-Null (Promega) was co-transfected with the pLA-luc. Luciferase assays
were performed using the Dual Luciferase Reporter Assay System (Promega)
following the manufacturer’s protocol. Luciferase activity was detected using a
Lumat LB9501 luminometer (Berthold Technologies, Oak Ridge, TN, USA). The
luciferase activity units were normalized to the Renillan luciferase control.
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GFP assay of p53 repression of LRBA promoter activity.

The LRBA

promoter vector driving GFP expression (LRBA-GFP) was transfected into
H1299 cells alone, or co-transfected with either the p53 wild-type or p53 DNAbinding mutant construct as previously described (see above). 24 hours posttransfection, the cells were washed in a 24-well plate two times in 1x PBS. Cells
were then lifted using 1x 0.25% Trypsin-EDTA (Gibco), pooled and washed with
1x PBS. Cells were then resuspended in staining media (PBS, 3% FBS, and
10mM HEPES) to a final concentration of 2x107 cells/ml. GFP levels were then
determined through flow cytometry on a FACSCalibur (Beckton Dickenson) flow
cytometer.

siRNA knockdown of LRBA expression.

LRBA siRNA oligonucleotides

were synthesized and purified by Dharmacon (Lafayette, CO, USA). At 1 day
before transfection, HeLa cells were seeded in a 24-well plate at 2 x 104 cells per
well. The LRBA siRNA (siRNA1:
5’-AACCAGCAAAGGUCUUGGCUA-3’,

siRNA2:

5’-

AAGGGCACUCUUUCUGUCACCUU-3’) and control siRNA (luciferase: 5’AACGUACGCGGAAUACUUCGA-3’,

scramble

siRNA:

5’-

CAGUCGCGUUUGCGACUGG-3’) duplexes at 50 nM were transfected into
HeLa cells following the previous protocol (Harborth et al., 2001). At 48–72 h
post-transfection, cells were trypsinized to obtain a single-cell suspension and
counted with a Coulter counter (Beckman coulter, Inc., Fullerton, CA, USA) or via
58

Trypan blue exclusion assay. Knockdown of LRBA mRNA levels was confirmed
by RT–PCR using primers 5’-GGTGGACCTACTGGAAAAATGTGAC-3’ and 5’TAGCCAAGACCTTTGCTGGTTC-3’.

Construction of the LRBA dominant negative mutant recombinant
adenovirus.

The replication-deficient recombinant adenovirus designated

AdBWGFP, which expresses GFP-tagged BW (BEACH-WD) region of mouse
Lrba, was generated by Adeno-X Tet-Off Expression Systems (Clontech)
following the manufacturer’s instructions. The recombinant adenoviral plasmid
was linearized and transfected into 293 cells (Clontech) using FuGENE 6 (Roche
Molecular Biochemicals), as recommended by the manufacturer. After 4–7 days,
cell suspension was cleared by centrifugation (1500 g) for 5 minutes, and the
supernatant containing ~ 103 viral particles were frozen at -80ºC. Stocks of high
viral titer were prepared following the protocol outlined by He et al., 1998.

Cell proliferation assays. CF-7 Tet-Off cells (Clontech) were seeded in a
96-well plate at 2 x 104 cells per well and cultured for 24 h. Cells were infected
with different titer of the recombinant AdBWGFP adenoviruses.

Doxycycline

(Clontech), which represses expression of the BWGFP fusion protein, was used
at 1 mg/ml. After 72 h post infection, cells were labeled with 3H thymidine (1 µCi
per well). After 18 hours, cells were harvested by trypsinization and counts per
minute (CPM) measured.
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Construction of shRNA plasmids.

The following oligos and their

complement oligos were synthesized and PAGE purified by Invitrogen, then
annealed and cloned into the pBS/U6 vector separately, following the methods
described

previously

(Sui

et

al.,

2002):

5-

‘(p)GGAGTGCTGGCTAGCTATAATTCAAGAGATTATAGCTAGCCAGCACTCC
CTTTTTG-3’;

Oligo-2

is

5’-

(p)GGTTGGTTGAAGTTGGAGAATTCAAGAGATTCTCC AACTTCAAC
CAACCCTTTTTG-3’. The murine SHIP (SH2-containing inositol phosphatase)
shRNA

vector[5’-

(p)GGGACGACTCTGCTGACTACATTTCAAGAGAATGTAGTCAGCAGAGTCG
TCCCTTTTTG-3’] used as a negative control was a gift from Drs John Ninos and
Shih-Chang Tsai at the H Lee Moffitt Cancer Center and Research Institute.
Gene sequences are in uppercase.

Colony-forming assays. HeLa cells were plated in a 24-well plate at 5 x
105/well 1 day before transfection.

Transfections were conducted using

Lipofectamine 2000 (Invitrogen) following the manufacturer’s protocol with some
modifications. Less (0.2 µl per well) Lipofectamine 2000 and more OPTI media
(200 µl per well) were used to reduce the toxicity. After 12 hours, 300 µl of
DMEM complete medium was added to each well. After another 12 hours, HeLa
cells in each well were trypsinized, transferred to one 100mm plate, and
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incubated for 10–14 days with G418 at 400 µg/ml. Colonies were stained with 0.5
ml of 0.005% Crystal Violet for 30 min to enable enumeration of colonies.

Western blot analysis.

For preparation of cellular protein, cells were

rinsed with PBS and lysed in RIPA containing 100 µg/ml phenyl-methylsulfonyl
fluoride, 2 µg/ml aprotinin, 2 µg/ml leupeptin and 1% NP-40 (lysis buffer). Protein
concentrations of cell lysates were determined by Coomassie Plus Protein Assay
Kit (Pierce). Cellular protein (100 µg) was loaded onto an 8–12% SDSPAGE gel
(Invitrogen) and transferred to PVDF or nitrocellular membranes. Membranes
were blocked for 1 hour at room temperature in 5% milk, washed with PBST
(PBS with 0.1%Tween-20) and incubated with the indicated antibodies for 1 or 24
hours.

Membranes were washed three times in PBST and HRP-conjugated

secondary antibody was added at 1:2,000 to 80,000 in 5% milk for 1 hour.
Membranes were washed and detected by ECL (Amersham Life Science,
Piscataway, NJ, USA) or the SuperSignal West Femto Kit (Pierce, Rockford, IL,
USA) and exposed to an X-ray film (Kodak, Rochester, NY, USA). In some
cases, blots were stripped with Restoret Western Blot Stripping Buffer (Pierce)
and probed a second time with other primary antibodies.

EGF stimulation assay. HeLa cells were seeded at 1 x 105/well in a24well plate. After 24 hours, the media was removed and replaced with 200 µl OPTI
media containing the AdBWGFP recombinant adenovirus with or without
doxycycline. After 24 h, the media was removed and replaced with 200 µl OPTI
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media containing either 0.5, 1, or 10 ng/ml of EGF. The cells were then incubated
at 37ºC for either 10 or 60 minutes and lysed with RIPA buffer. Western blot
analysis was then performed as described above.

Statistical analysis. Prism v3.0. was used to make all column bar graphics
and calculate the statistical significance of the experimental results by using a
two tailed unpaired T-test at 95% confidence intervals. P<0.05 was considered to
be

statistically

significant

and

is
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marked

with

*

in

the

figures.

Chapter Two
RNAi Mediated Inhibition of SHIP-1 Expression in Mouse and Human Cells

Introduction

PI3 Kinase and the Akt pathways.

The PI3 Kinase (PI3-K) family of

enzymes regulate phosphorylation of various phospholipid species (Deane &
Fruman, 2004).

Through this mechanism of action, this family of enzymes

regulates several critical cellular processes such as proliferation, migration, cell
cycle initiation, and survival (Rauh et al., 2003). Furthermore, PI3-K is involved
in several disease processes such as diabetes and cancer (Cantley, 2002). One
mechanism in particular involves the conversion of PI-3,4-P (PIP-2) to PI-3,4,5-P
(PIP-3) by the Class Ia PI3-Ks in higher eukaryotes. This functions to create an
abundance of PIP-3 which acts to recruit proteins with Pleckstrin Homology
domains to the cellular membrane. This mechanism functions to regulate several
important signal transduction processes such as the activation of the kinase
Akt/PKB (Figure 24).
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Figure 24. The role of PI3-K and SHIP in the activation of Akt
PI3-K catalyzes the conversion of PIP-2 to PIP-3 which activates the kinase
PDK1. PDK1 then activates Akt through phosphorylation. SHIP opposes the
PI3-K pathway through its phosphatase activity which catalyzes the conversion of
PIP-3 to PIP-2.
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Akt/PKB is a serine/threonine kinase and a member of the protein kinase
A, G, and C superfamily. This protein is involved in several signal transduction
pathways that govern cellular functions such as proliferation, metabolism,
apoptosis, and transcriptional regulation.

Furthermore, the Akt pathway has

been characterized as one of the most important pathways in the regulation of
cell survival (Song, Ouyang, & Bao, 2005).
One of the ways that Akt influences cell survival is through the negative
regulation of apoptosis. This involves the regulation of a pro-apoptotic member
of the Bcl-2 family of proteins known as BAD. BAD associates anti-apoptotic
members of the Bcl-2 family, such as Bcl-xl through protein-protein interaction.
Akt regulates BAD’s function by phosphorylation of Serine residue at position
136.

Once phosphorylated, BAD associates with the 14-3-3 protein and is

retained in the cytoplasm, thus allowing anti-apoptotic Bcl-2 family members to
prevent apoptosis (Figure 25, (Jorissen et al., 2003)).
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Figure 25. The role of Akt and BAD in cell survival
Akt is activated by cell survival signals through phosphorylation. Activated Akt
then phosphorylates BAD which then dissociates from Bcl-xl. BAD then binds to
the 14-3-3 protein and is retained in the cytosol and Bcl-xl is free to function in
cell survival related processes.
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As previously mentioned, the activation of Akt occurs after recruitment to
the plasma membrane by the binding of PIP-3 in its Pleckstrin Homology (PH)
domain (Andjelkovic et al., 1997). There, Akt activity is primarily regulated at two
phosphorylation sites, threonine 308 which is located in the activation loop and
serine 473 which is located in the C-terminal regulatory domain (Alessi et al.,
1996; Bayascas & Alessi, 2005).

Phosphorylation at Thr308 only partially

activates Akt, and phosphorlylation of both Thr308 and Ser473 is required for
complete activation. However, phosphorylation of Ser473 alone is insufficient to
activate Akt. Akt is phosphorylated at the Thr308 position by phosphoinositide
dependent kinase 1 (PDK1) (Figure 24), while the mechanism of phosphorylation
of Ser473 remains unclear (Song, Ouyang, & Bao, 2005).

The SH2-containing Inositol 5’ Phosphatase gene and Natural Killer cells.
The SH2-containing Inositol 5’ Phosphatase (SHIP) gene, also known as SHIP-1,
encodes for a 145 kDa protein that catalyzes the conversion of PI-3,4,5-P (PIP3)
to PI-3,4-P (PIP2). This action functions to negatively regulate the PI3K pathway
and thus Akt activation (Figure 24). There are several isoforms of the SHIP
protein including SHIP-1 and SHIP-2.

SHIP-1 is primarily expressed in the

hematopoietic compartment while SHIP-2 is believed to be ubiquitously
expressed in every other cell type (Sly, Rauh, Kalesnikoff, Buchse, & Krystal,
2003).
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Previous work has shown that SHIP-1 -/- permit of engraftment allogeneic
tissues, such as bone marrow. This is due to compromised rejection by SHIP -/Natural Killer (NK) cells and which is attributed to reduced Graft Versus Host
Disease (GVHD) due to an expansion of myeloid suppressor cells (Ghansah et
al., 2004; J. W. Wang et al., 2002).

Furthermore, mouse germ line SHIP

deficient mice show a significant disruption in the NK receptor repertoire of NK
cells and this phenotype most likely contributes to GVHD evasion (J. W. Wang et
al., 2002).
Natural Killer (NK) cells are lymphocytes part of the innate immune system
(Lanier, 2005). These cells are activated to kill cells in distress (such as cancer
cells and virally infected cells) through the expression of a complex repertoire of
receptors (Makrigiannis & Anderson, 2003). These receptors can either activate
or inhibit NK cell mediated killing primarily through the presence of ITAM
(immunoreceptor tyrosine activation motif) or ITIM (immunoreceptor tyrosine
inhibiting motif) domains in their cytoplasmic domains (Lanier, 2005).
Previous studies of the loss of SHIP-1 function relied on genetic studies in
knockout mice as well as over-expression of SHIP-1 and antisense approaches
in human cells. However, with the discovery of RNAi as a tool to study the loss
of function in vitro, we set out design both mouse and human SHIP-1 specific
siRNA’s.

Furthermore, human SHIP-1 specific siRNA’s were used to test

whether SHIP-1 regulates Akt activation NK cells.
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Results

Generation of human and mouse SHIP-1 specific siRNA’s.

To inhibit

SHIP-1 expression in mice, several siRNA’s were designed targeting several
locations of the SHIP-1 cDNA sequence. These siRNA’s were then tested for
their ability to knock-down SHIP-1 protein levels in vitro by nucleofection into the
mouse macrophage cell line, RAW264.7 which is known to express SHIIP-1 at
high levels as determined through western blot analysis.

Results show

reproducible inhibition of SHIP-1 expression for siRNA-5, 7, 8, and 9 (Figure 26).
As with the mice siRNA’s, human SHIP-1 specific siRNA’s were designed
targeting two different regions of the SHIP-1 cDNA sequence. These siRNA’s
were then nucleofected into the human natural killer cell line, NKL. Results show
that both siRNA’s h1 and h2 are effective at knocking down SHIP-1 expression
as compared to NKL’s nucleofected with a luciferase-specific control. However,
siRNA-h1 was more effective at inhibiting SHIP-1 protein expression.
Furthermore, this inhibition was significant at 24, 48, and 73 hours (Figure 23).
Thus we have 2 highly effective siRNA’s to use in studying the loss of SHIP-1 in
human cells.
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Figure 26. Knockdown of mouse SHIP-1 levels in the mouse macrophage cell
line RAW264.7.
Significant knockdown of SHIP-1 protein levels is evident 48 hours after
transfection of SHIP-1 specific siRNA’s 5, 7, 8, and 9 as compared to a nonspecific control, C.
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Figure 27. Inhibition of SHIP-1 expression in human NK cells.
Significant knockdown of SHIP-1 protein expression is evident in the human NK
cell line NKL with the two SHIP-1 specific siRNA’s h1 and h2 as compared to a
non-specific control (top). Significant knockdown of SHIP-1 levels is evident 24
(top), 48 and 72 hours post transfection (bottom) as compared to a non-specific
control, C.
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SHIP-1 is involved in regulating Akt activation in human NK cells. As
previously mentioned, previous results have shown that activated Akt levels are
elevated in mouse SHIP-/- NK cells as compared to mouse SHIP+/+ NK cells.
To determine whether SHIP-1 plays a role in the activation of AKT in human NK
cells, NKL cells were nucleofected with the highly effective siRNA-h1 or control
siRNA’s as previously described. These cells were then lysed 48 hours after
nucleofection and probed for p-Akt (Thr308), SHIP-1, and β-Actin. Results show
elevated levels of p-Akt (Thr308) in cells in which SHIP-1 protein expression was
inhibited as compared to NKL cells transfected with non-specific control siRNA’s
(Figure 28). Furthermore, β-Actin levels demonstrate equal protein loading.
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Figure 28. SHIP-1 influences the activation of Akt
NKL cells nucleofected with SHIP-1 specific siRNA’s show increased levels of
activated Akt as compared with cells nucleofected with a non-specific control.
Actin levels show equal loading of protein.
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Discussion

RNAi is a relatively new technique utilized to study the absence of
expression of a particular gene of interest in cell lines. Previously, this was
limited to the tedious and time consuming process of generating knock out mice,
and to antisense approaches that induced interferon responses. Therefore, we
set out design SHIP-1 specific siRNA’s to study the loss of SHIP-1 expression in
both mouse and human cells. Our results show a significant reduction in SHIP-1
protein levels in both a mouse macrophage cell line and a human natural killer
cell line. These new tools will allow for the further elucidation of the role this
enzyme plays in critical immune functions.
Human NK cells nucleofected with the highly effective human SHIP-1
specific siRNA-h1 showed an increase in activated Akt levels as compared to
human NK cells nucleofected with a non-specific control. This finding not only
confirms what was previously observed in mouse SHIP-/- NK cells, but suggests
that SHIP-1’s role in opposing Akt activation is highly significant as the effect was
observed only 48 hours after knock-down of SHIP-1 expression. These findings
are also in agreement with what was observed in human T Cells (Horn et al.,
2004). In this instance, SHIP-1 expression was restored in Jurkat cells, which
are SHIP-1 deficient, and a significant reduction of Akt kinase activity was
observed. These results provide fodder for future investigation as to what role
SHIP-1 plays in the Akt pathway of human NK cells.
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Materials and Methods

siRNA Design. siRNA’s were designed using the siDesign feature of the
Dharmacon website (http://www.dharmacon.com/sidesign/). Mouse sequences
used were as follows: 1. sense: 5’-GAAGAUCACGUCCUGGUUUdTdT-3’,
antisense:

5’-AAACCAGGACGACGUGAUCUUCdTdT-3’

UGGUCCUGGCACUGUAGAUdTdT-3’,
AUCUACAGUGCCAGGACCAdTdT-3’,
UCCAAACdTdT-3’,
sense:

antisense:

2.

sense:

antisense:
3.

sense:

5’-

5’-UGAGAUGAUCAA

5’-GUUUGGAUUGAUCAUCUCAdTdT-3’,

5’-GACGACUCUGCUGACUACAdTdT-3’,

AGUCAGCAGAGUCGUCdTdT-3’,

antisense:

5.

sense:

AUCCAGUGGAAUGAAAdTdT,

AGAUGAUCAAUCCAAACUAdTdT-3’,

6.
antisense:

4.

5’-UGU
5’-UGA

antisense:

UUUCAUUCCACUGGAUUCAdTdT,

5’-

5sense:

5’-

5’-UAGUUUGGAUUGAUC

AUCUdTdT-3’, 7. sense: 5’-AGACUACCGUGACAACACAdTdT-3’, antisense: 5’UGUGUUGUCACGGUAGUCUdTdT-3’, 8.

sense: 5’- UGUGUUAAGUGCUUU

AUG AdTdT-3’, antisense: 5’-UCAUAAAGCACUUAACACAdTdT-3’, 9. sense: 5’AAACCAUCGGUCUCUUAGAdTdT-3’,
AUGGUUUdTdT-3’.

Human

antisense:

sequences

GGAAUUGCGUUUACACUUAdTdT-3’,
CAAUUCCdTdT-3’,

h2.

sense:

used
antisense:

5’-UCUAAGAGACCG
were:

h1.

sense:

5’-

5’-UAAGUGUAAACG

5’-AUUUGCGUUUACACUUACAdTdT-3’,
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antisense: 5’-UGUAAGUGUAAACGCAAUUdTdT-3’.

The luciferase specific

control siRNA siControl #2 (Dharmacon) was used as a non-specific control.

Cell lines.

The mouse macrophage cell line RAW264.7 was grown in

DMEM, 10% FBS, and 1% Penicillin and Streptomycin. The human natural killer
cell lines NKL and NK3.3 were grown in RPMI 1640, 10% FBS, 1% Penicillin and
Streptomycin, 200U/ml of Proleukin 2 (Chiron), and 5ug/ml of Plasmocin
(InvivoGen).

Nuleofection of siRNA’s.

All siRNA’s were transfected using the

Nucleofection system from Amaxa. For the RAW264.7 cells, 2 x 106 cells were
nucleofected per siRNA with solution V kit following the manufacturer’s
instructions at the setting T-24. 4.0ug of pmaxGFP vector (Amaxa) or 1.5ug of
the corresponding siRNA was used for each individual nucleoporation. For the
NK3.3 and NKL cell lines, 2x106 cells were nucleofected with solution V following
the manufacturer’s instructions at the setting O-17. Again, 4.0ug of pmaxGFP
vector (Amaxa) or 1.5ug of the corresponding siRNA was used for each
individual nucleoporation. Cell were incubated for the indicated period of times
and either tested for GFP expression by fluorescent microscopy or lysed for
Western Blot analysis of protein levels.

Western Blot Analysis.

Western Blot analysis was performed as

previously described (see page x). The following antibodies were used: anti77

SHIP-1, P1C1 (Santa Cruz Biotechnology), anti-β-Actin, C-11 (Santa Cruz
Biotechnology), and phopho-Akt(Thr308) (Cell Signaling Technology). A BCA
protein assay (Promega) was performed following the manufacturer’s protocol to
ensure equal loading of protein following.
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